1032824-54-6 Usage
General Description
GSK1292263 (HCl) is a selective and potent inhibitor of the receptor-interacting protein 1 (RIP1) kinase, an essential component of the tumor necrosis factor (TNF) signaling pathway, which plays a crucial role in inflammation and cell death. GSK1292263 (HCl) has been shown to effectively block RIP1 kinase activity, resulting in decreased production of pro-inflammatory cytokines and inhibition of programmed cell death. GSK1292263 (HCl) has potential therapeutic applications in the treatment of inflammatory and autoimmune diseases, as well as in the prevention of tissue damage associated with ischemia-reperfusion injury. Additionally, GSK1292263 (HCl) has been studied for its potential role in cancer treatment, as RIP1 kinase has been implicated in the regulation of cell survival and proliferation.
Check Digit Verification of cas no
The CAS Registry Mumber 1032824-54-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,2,8,2 and 4 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1032824-54:
(9*1)+(8*0)+(7*3)+(6*2)+(5*8)+(4*2)+(3*4)+(2*5)+(1*4)=116
116 % 10 = 6
So 1032824-54-6 is a valid CAS Registry Number.
1032824-54-6Relevant articles and documents
BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS
-
Page/Page column 82, (2010/03/02)
The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
